Zoledro denk

Description

Zoledronic acid 4mg/5ml

• One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate)
• Zoledro-Denk prevents skeletal related events in patients with advanced malignancies involving bone fractures in patients with cancers, and treats tumor-induced hypercalcemia, osteoporosis (post-menopausal women and in men; even with a recent low-trauma hip fracture; also associated with long-term systemic glucocorticoid therapy) and Paget’s disease of the bone
• Strong inhibition of osteoclastic bone resorption
• Showed significant benefit in osteoporosis as well as reduction in mortality after hip fraction